Your browser doesn't support javascript.
loading
Clonal dominance defines metastatic dissemination in pancreatic cancer.
Ho, I-Lin; Li, Chieh-Yuan; Wang, Fuchenchu; Zhao, Li; Liu, Jingjing; Yen, Er-Yen; Dyke, Charles A; Shah, Rutvi; Liu, Zhaoliang; Çetin, Ali Osman; Chu, Yanshuo; Citron, Francesca; Attanasio, Sergio; Corti, Denise; Darbaniyan, Faezeh; Del Poggetto, Edoardo; Loponte, Sara; Liu, Jintan; Soeung, Melinda; Chen, Ziheng; Jiang, Shan; Jiang, Hong; Inoue, Akira; Gao, Sisi; Deem, Angela; Feng, Ningping; Ying, Haoqiang; Kim, Michael; Giuliani, Virginia; Genovese, Giannicola; Zhang, Jianhua; Futreal, Andrew; Maitra, Anirban; Heffernan, Timothy; Wang, Linghua; Do, Kim-Anh; Gargiulo, Gaetano; Draetta, Giulio; Carugo, Alessandro; Lin, Ruitao; Viale, Andrea.
Afiliação
  • Ho IL; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
  • Li CY; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang F; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
  • Zhao L; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Liu J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yen EY; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Dyke CA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Shah R; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
  • Liu Z; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Çetin AO; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Chu Y; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
  • Citron F; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Attanasio S; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Corti D; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Robert-Rössle-Str. 10, 13125 Berlin, Germany.
  • Darbaniyan F; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Del Poggetto E; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Loponte S; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Liu J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Soeung M; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Chen Z; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jiang S; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jiang H; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
  • Inoue A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gao S; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
  • Deem A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Feng N; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ying H; TRACTION platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kim M; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Giuliani V; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Genovese G; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang J; TRACTION platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Futreal A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Maitra A; TRACTION platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Heffernan T; Department of Cellular and Molecular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang L; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Do KA; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Robert-Rössle-Str. 10, 13125 Berlin, Germany.
  • Gargiulo G; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Draetta G; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Carugo A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lin R; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Viale A; TRACTION platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sci Adv ; 10(11): eadd9342, 2024 Mar 15.
Article em En | MEDLINE | ID: mdl-38478609
ABSTRACT
Tumors represent ecosystems where subclones compete during tumor growth. While extensively investigated, a comprehensive picture of the interplay of clonal lineages during dissemination is still lacking. Using patient-derived pancreatic cancer cells, we created orthotopically implanted clonal replica tumors to trace clonal dynamics of unperturbed tumor expansion and dissemination. This model revealed the multifaceted nature of tumor growth, with rapid changes in clonal fitness leading to continuous reshuffling of tumor architecture and alternating clonal dominance as a distinct feature of cancer growth. Regarding dissemination, a large fraction of tumor lineages could be found at secondary sites each having distinctive organ growth patterns as well as numerous undescribed behaviors such as abortive colonization. Paired analysis of primary and secondary sites revealed fitness as major contributor to dissemination. From the analysis of pro- and nonmetastatic isogenic subclones, we identified a transcriptomic signature able to identify metastatic cells in human tumors and predict patients' survival.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Ecossistema Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Ecossistema Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article